13 results
SC 13E3/A
EX-99
STSA
Satsuma Pharmaceuticals Inc
8 Jun 23
Going private transaction (amended)
9:16am
December 31, 2022
Total assets
Revenue
Operating profit*1)
Net loss
Comprehensive loss
Net loss per share (US$)
R&D expenses
Cash, cash equivalents … and marketable securities
Negative earnings were posted mainly due to R&D costs for STS101 for which Satsuma conducted Phase 3 clinical studies in the US
SC TO-C
EX-99.2
STSA
Satsuma Pharmaceuticals Inc
17 Apr 23
Information about tender offer
6:08am
share (US$)
R&D expenses*3)
Cash, cash equivalents and marketable securities
From Satsuma’s Form 10-K filed with the U.S. Securities and Exchange
8-K
EX-99.2
STSA
Satsuma Pharmaceuticals Inc
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
equipment required Drug-device combinations are challenging to genericize STS101 is the result of extensive formulation and device R&D over a long period
8-K
EX-99.2
v9v62s2nr1yy
1 Mar 21
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
12:00am
10-K
3b5d8dz156u79q
10 Mar 20
Annual report
4:20pm
424B4
d8m2a0dbnpwyryq
13 Sep 19
Prospectus supplement with pricing info
5:08pm
S-1/A
g0ibziv70be8ja6ew9c
3 Sep 19
IPO registration (amended)
6:12am
S-1
mzy8j6p73fqmkdux8r
16 Aug 19
IPO registration
5:15pm
DRS/A
xw93i1eyp6697si qy
2 Aug 19
Draft registration statement (amended)
12:00am
DRS
0whwjjbi5wyp y8qb
21 Jun 19
Draft registration statement
12:00am
- Prev
- 1
- Next